Pre-made Letolizumab benchmark antibody ( Single Domain Variable Fragment;H, anti-CD40LG therapeutic antibody, Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Letolizumab biosimilar, Single Domain Variable Fragment;H, Anti-CD40LG Antibody: Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Letolizumab (INN; development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-307-1mg	1mg	Inquiry
GMP-Bios-ab-307-10mg	10mg	Inquiry
GMP-Bios-ab-307-100mg	100mg	Inquiry
GMP-Bios-ab-307-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Letolizumab biosimilar, Single Domain Variable Fragment;H, Anti-CD40LG Antibody: Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L therapeutic antibody
INN Name	Letolizumab
Target	CD40LG
Format	Single Domain Variable Fragment;H
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	na
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute
Conditions Approved	na
Conditions Active	Graft-versus-host disease;Idiopathic thrombocytopenic purpura
Conditions Discontinued	na
Development Tech	na